[{"id":"743006a6-c939-4023-8010-4e3aee085ae3","acronym":"E7386-J081-102","url":"https://clinicaltrials.gov/study/NCT04008797","created_at":"2022-06-28T02:54:50.954Z","updated_at":"2025-02-25T15:18:13.404Z","phase":"Phase 1/2","brief_title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","source_id_and_acronym":"NCT04008797 - E7386-J081-102","lead_sponsor":"Eisai Inc.","biomarkers":" EGFR • KRAS • BRAF • MSI","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type","tags":["EGFR • KRAS • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Lenvima (lenvatinib) • doxorubicin hydrochloride • E7386"],"overall_status":"Recruiting","enrollment":" Enrollment 301","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-11"},{"id":"6983d949-ecb2-40d9-9de6-9dd357d15cfa","acronym":"KEYNOTE-C83","url":"https://clinicaltrials.gov/study/NCT05091346","created_at":"2021-10-25T11:52:57.520Z","updated_at":"2025-02-25T16:16:50.707Z","phase":"Phase 1/2","brief_title":"A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors","source_id_and_acronym":"NCT05091346 - KEYNOTE-C83","lead_sponsor":"Eisai Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • E7386"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 10/27/2021","start_date":" 10/27/2021","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 10/15/2024","study_completion_date":" 10/15/2024","last_update_posted":"2024-10-24"},{"id":"a47ddf13-3816-49fc-80b2-c615e6b61c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT03264664","created_at":"2023-11-04T04:12:31.080Z","updated_at":"2024-07-02T16:34:27.421Z","phase":"Phase 1","brief_title":"Study of E7386 in Participants With Selected Advanced Neoplasms","source_id_and_acronym":"NCT03264664","lead_sponsor":"Eisai Inc.","biomarkers":" CTNNB1","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/27/2017","start_date":" 07/27/2017","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-06-11"},{"id":"d1c8d534-b991-4bdd-aee5-250c8074853d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03833700","created_at":"2023-07-12T22:09:04.322Z","updated_at":"2024-07-02T16:35:16.167Z","phase":"Phase 1","brief_title":"A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)","source_id_and_acronym":"NCT03833700","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" RNF43 • APC • AXIN1 • ZNRF3","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation","tags":["RNF43 • APC • AXIN1 • ZNRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/05/2019","start_date":" 03/05/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-06"}]